Positive result in Phase III trial of Kovid pill, says

new Delhi: Drug firm Hetero on Saturday announced positive results of Phase III trials of an investigational oral antiviral COVID-19 drug Movfor (molnupiravir).

The results, presented as an oral abstract at the Retrovirus and Opportunistic Infections (CROI) Conference held approximately February 12-16, 2022, demonstrated that mollupiravir reduced the risk of hospitalization with standard of care (SOC) by 65 percent. reduced more than For SoC alone.

The Hyderabad-based drugmaker said in a statement that initial viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug.

It added that no casualties were reported during the study.

Under Phase III trials, one of the studies involved 1,218 COVID-19 patients, it said. Eligible patients enrolled in the study were administered with molanupiravir capsules (800 mg twice daily) for five days, within five days of symptom onset.

Hetero entered into a non-exclusive voluntary licensing agreement with MSD in April 2021 for the manufacture and distribution of Molnupiravir for the treatment of COVID-19.

Under this licensing deal, Hetero was allowed to expand the reach of molnupiravir in India and other low and middle income countries (LMICs), following approval for emergency use authorization by local regulatory agencies.

(Except for the title, this story has not been edited by NDTV staff and is published from a syndicated feed.)

    ,